The Future Of Nano Technology
- Alan Watts
- Anti-Aging Medicine
- David Sinclair
- Gene Medicine
- Gene therapy
- Genetic Medicine
- Genetic Therapy
- Hormone Replacement Therapy
- Human Genetic Engineering
- Human Reproduction
- Integrative Medicine
- Life Skills
- Longevity Medicine
- Machine Learning
- Medical School
- Nano Medicine
- Parkinson's disease
- Quantum Computing
- Regenerative Medicine
- Stem Cell Therapy
- Stem Cells
- Researchers combine immunotherapy with nano-particles to kill cancer cells – The Brussels Times
- New Approaches in Breast Cancer Therapy Through Green Nanotechnology a | IJN – Dove Medical Press
- Complete Overview of Cancer Nanomedicine Market to Witness High Rate of Growth in Forthcoming Years – Fusion Science Academy
- Controlled phage therapy hints at future alternative to antibiotics – New Atlas
- Healthcare IT Market trends research and projections – GroundAlerts.com
|Search Immortality Topics:|
Category Archives: Nano Medicine
Saturday, 11 January 2020
An international group of scientists has reported on a technique to kill cancer cells in mice using a combination of immunotherapy and nano-particles of copper oxide.
The group is made up of researchers from the universities of Leuven, Bremen in Germany and Ioannina in Greece, as well as the Leibnitz Institute for Materials Engineering, also in Bremen. Their results are published in English in the journal Angewandte Chemie.
The bodys own immune system is being used more and more often in medical treatments for cancer, but not always successfully.
The team discovered that cancer cells are very sensitive to nano-particles of copper oxides, which dissolve in the body and are fatal to the cancer cells. However, using copper oxide particles alone did not prevent the cancer from returning.
But when the nano-particles are coupled with the bodys own immune system, and found that not only were the cancer cells killed, the bodys immune system learned to attack cancer cells on its own, and they were never able to re-establish. To test the result, after treatment with the reinforced immune cells, the team re-injected cancer cells into the now-healthy mice. The immune system in the mice was now able to recognise the cancer, and it was wiped out before it had a chance to take hold.
The team argues that the technique could be effective in a range of different cancers those caused by a mutation in the tumour protein TP53. Those include forms of cancer of the breast, lung, ovary and colon.
As far as I can tell, this is the first time that metal oxides have been used to fight cancer cells effectively in living models, commented Professor Stefaan Soenen of the department of imaging and pathology of the KULeuven. Now we want to look at other metal nano-particles and identify which particles influence which types of cancer. That would result in an extensive database.
The team now plans to test cancer cells based on tissue taken from cancer patients. If the results are as positive, Prof. Soenen plans to set up a clinical trial using human subjects.
Nano-medicine is becoming more and more popular in the US and Asia, but Europe is falling behind. It is a challenge to achieve progress, since physicians and engineers often speak a different language. We need more inter-disciplinary cooperation, to allow us better to understand each other, and to build upon each others knowledge.
Alan HopeThe Brussels Times
Menka Khoobchandani, 1, 2 Kavita K Katti, 1, 2 Alice Raphael Karikachery, 1, 2 Velaphi C Thipe, 1, 2 Deepak Srisrimal, 3 Darsha Kumar Dhurvas Mohandoss, 3 Rashmi Dhurvas Darshakumar, 3 Chintamani M Joshi, 3 Kattesh V Katti 1, 2, 4
1Department of Radiology, University of Missouri, Columbia, MO 65212, USA; 2Institute of Green Nanotechnology, University of Missouri, Columbia, MO 65212, USA; 3Dhanvantari Nano Ayushadi Pvt Ltd, Chennai 600017, India; 4Department of Physics, Department of Pharmacology, Department of Biological Engineering, University of Missouri Research Reactor (MURR), University of Missouri, Columbia, MO 65212, USA
Correspondence: Kattesh V KattiDepartment of Radiology, University of Missouri, One Hospital Drive, Columbia, MO 65212 USATel +1 573 882-5656Email KattiK@health.missouri.edu
Purpose: The overarching objective of this investigation was to investigate the intervention of green nanotechnology to transform the ancient holistic Ayurvedic medicine scientifically credible through reproducible formulations and rigorous pre-clinical/clinical evaluations.Methods: We provide, herein, full details: (i) on the discovery and full characterization of gold nanoparticles-based Nano Swarna Bhasma (henceforth referred to as NSB drug); (ii) In vitro anti-tumor properties of NSB drug in breast tumor cells; (iii) pre-clinical therapeutic efficacy studies of NSB drug in breast tumor bearing SCID mice through oral delivery protocols and (iv) first results of clinical translation, from mice to human breast cancer patients, through pilot human clinical trials, conducted according to the Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy (abbreviated as AYUSH) regulatory guidelines of the Government of India in metastatic breast cancer patients.Results: The preclinical in vitro and in vivo investigations, in breast tumor bearing mice, established unequivocally that the NSB Nano-Ayurvedic medicine-gold nanoparticles-based drug is highly effective in controlling the growth of breast tumors in a dose dependent fashion in vivo. These encouraging pre-clinical results prompted us to seek permission from the Indian Governments holistic medicine approval authority, AYUSH, for conducting clinical trials in human patients. Patients treated with the NSB drug capsules along with the standard of care treatment (Arm B) exhibited 100% clinical benefits when compared to patients in the treatment Arm A, thus indicating the tremendous clinical benefits of NSB drug in adjuvant therapy.Conclusion: We have succeeded in clinically translating, from mice to humans, in using proprietary combinations of gold nanoparticles and phytochemicals to develop the Nano-Ayurvedic drug: Nano Swarna Bhasma (NSB), through innovative green nanotechnology, for treating human metastatic breast cancer patients.
Keywords: gold nanoparticles, mangiferin, mango peel, Nano Swarna Bhasma, NSB, triple negative breast tumor, pilot clinical
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
See the original post here:
New Approaches in Breast Cancer Therapy Through Green Nanotechnology a | IJN - Dove Medical Press
Complete Overview of Cancer Nanomedicine Market to Witness High Rate of Growth in Forthcoming Years – Fusion Science Academy
The Global Cancer Nanomedicine Market Research Report is released byMarket Research Explore, aiming at providing readers the ability to review the pivotal dynamics and numerous segments of the industry. A thorough regional analysis is also conducted in the report by our expert analysts on the major geographical regions to offer Cancer Nanomedicine market players opportunities to dominate and expand their business reach across the globe. The study also highlights precise assessments of market size, share, demand, revenue, sales volume, and growth rate of the global Cancer Nanomedicine market.
The global Cancer Nanomedicine market has been expanding vigorously since the last decade with a steady growing CAGR. Observing growth-boosting factors such as rapidly surging demand for the Cancer Nanomedicine , rising disposable incomes, a swelling population of developed countries, stable economic system, improved infrastructures, and product awareness, the global Cancer Nanomedicine market is anticipated to grow more swiftly during the forecast period of up to 2026. The international revenue generation is also expected to be influenced by the development momentum of the industry that can allure more individuals to invest and become a part of the booming industry.
Get Sample of Global Cancer Nanomedicine Market Report 2020:https://www.marketresearchexplore.com/report/global-cancer-nanomedicine-market-report-2019-competitive-landscape-trends-and-opportunities/302423#enquiry
Concise review of global Cancer Nanomedicine market rivalry landscape:
The research study further emphasizes the impulsively swapping competitor landscape, one of the pivotal facets impacting on market development. The Cancer Nanomedicine market report studies how competitors deliver better products and pose robust challenges for their rivals by executing product research, innovations, developments, and technology adoptions. The report also analyzes their products and services at a minute level and explores their way of competition to increase revenue share and reach in the market at both the national and international levels.
Their financial assessments are also involved in the report to enable other market players and investors to comprehend the strengths, weaknesses, and market positions of their rivals. Companies manufacturing base, Cancer Nanomedicine production capacities, volume, processes, raw material details, organizational structure, major vendors, and corporate alliance are also evaluated in the report. The global Cancer Nanomedicine market report also sheds light on their effective business strategies, which include mergers, acquisitions, ventures, amalgamations, as well as product launches, and brand promotions.
Major influential factors in the global Cancer Nanomedicine market:
The study also elucidates extensive analysis of changing Cancer Nanomedicine market dynamics, contemporary trends, consumption tendencies, uneven demand-supply ratios, volatile pricing systems, market fluctuations, restraints, limitations, as well as growth-boosting forces, as all these have been considered to influence the market structure in a positive/negative manner. Additionally, provincial trade policies, international trade disputes, social, political, atmospheric, and financial circumstances are also examined in the report that falls under the industry environment and deemed to pose an impact on market development.
Get Expansive Exploration of Global Cancer Nanomedicine Market 2020
Pivotal segments of the global Cancer Nanomedicine market:
The global Cancer Nanomedicine market has been divided into extremely significant segments such as types, applications, regions, and end-users. The report offers a profound rundown based on each market segment with consideration of their market acceptance, current performance, profitability, demand, production, and growth prospects. Regions including North America, Europe, South America, Middle East & Africa, and the Asia Pacific are also included in in-depth regional analysis of the Cancer Nanomedicine market.
You can contact us at[emailprotected]in case you need detailed information or have queries regarding the market study.
We are a vibrant market research company which is focused on catering to more and more people day by day. Our research company is one of a few reliable market research report companies in todays date.
Phages, viruses that thrive by infecting bacteria, have long been mooted as a potential replacement for antibiotics. But where antibiotics pose the problem of the bacteria they target mutating into dangerous resistant strains, phages pose risks due to their own fast-paced evolution, though those risks are poorly understood.
But new research suggests it may be possible to mitigate those risks. Left to nature, particular phages are able to seek out and destroy particular types of bacteria. But here its only the seeking that the researchers are interested in, using the phages to deliver a payload of gold nanorods which, with the help of light, destroy both the target bacteria and their phages at once. If youll forgive the grim analogy, you can think of the phage as the guidance system and the nanorods the warhead of this particular antibacterial guided missile.
What we did was to conjugate the phages to gold nanorods, UC Santa Barbaras Irene Chen explains in a press release. If you thought conjugation was something that happened only to verbs, dont panic: it can also simply mean to join or couple. When these nanorods are photo-excited, they translate the energy from light to heat, and that creates very high local temperatures.
The so-called phanorod combinations of nanorods and phages were added to in-vitro cultures of mammal cells with an added bacteria biofilm. They were then exposed to light in near-infrared wavelengths to cause the all-important photo-excitement. The resulting heat kills both the bacteria and the phage.
In experiments, the phanorods successfully destroyed the potent human pathogens E. coli, P. aeruginosa and V. cholerae. Its important to note that the phanorods also destroyed 20 percent of the mammal cells in the culture, which the research categorizes as a low rate of damage.
This issue of whether it damages mammalian tissues is very important, Chen explains. Work in nanotechnology and nanomedicine treating bacterial infections indicates that when its non-targeted, it really does burden the surrounding tissues.
As well as the unpredictable nature of unchecked phage evolution, there are other issues with their historical use. They can potentially carry toxins, and its hard to gauge the success of the treatment. You might see it completely work or you might see it completely fail, but you dont have the kind of dose response you want, Chen explains. But this new controlled approach to phage therapy could potentially mitigate these issues as well.
The teams research will go on to look at more phages to target more types of bacteria, as well as exploring photothermal methods to treat several bacterial infections at once. However, the work is very much at the research stage, and theres no suggestion of clinical use at this stage.
The teams research was published Monday in Proceedings of the National Academy of Sciences. Its free to read online.
Sources: UC Santa Barbara, Proceedings of the National Academy of Sciences
The consumerization in healthcare information technology has reached a tipping point, the impact of which has been felt across healthcare IT market. The need to ensure comfort and security for patients has brought about a major transformation in the medical sphere, leading to a path-breaking intersection of IT and healthcare. The deployment of IT has equipped the healthcare industry with nanomedicine, virtual healthcare, 3D printing, robot-assisted surgery, and more. These advancements, aided by the investments by the governments worldwide, have brought about a massive change in the healthcare IT industry outlook.
The global healthcare IT market has also gained traction on account of innumerable parameters, prominent among them being, the increasing geriatric populace and the changing consumer lifestyles. Indeed, these have led to a spate of diseases worldwide, consequently surging the demand for a highly sophisticated healthcare IT network in order to lower errors in administration processes and ensure efficient medical data and patient record management.
Request sample copy of this report @ http://decresearch.com/request-sample/detail/232
Consumer expectations have also changed in the last decade or so, leading to healthcare providers focusing on prioritizing efficient management of healthcare data. This has subsequently led to the implementation of innovative technologies in the medical ecosphere, augmenting the revenue graph of the global healthcare IT market. Indeed, estimates claim that healthcare IT industry is expected to exceed $441.8 billion by the year 2025.
While numerous IT solutions are deployed in the healthcare space, one of the most significant ones is that of electronic health records. Undeniably, healthcare IT industry has gained much via rapid adoption of the EHR technology by healthcare specialists in the U.S. and other economies. According to the National Electronic Health Records Survey, 2017, approximately 9 out of 10 office-based physicians had adopted any type of EHR, while certified EHRs were adopted by 4 out of 5 office-based physicians. Since 2008, the rate of EHR adoption has more than doubled from 42 percent to nearly 86 percent in 2017. The accelerated adoption of EHR will thus drive the growth graph of healthcare IT industry from electronic health records. As a matter of fact, estimates claim that EHR-based healthcare IT market size will cross $97.8 billion by 2025.
Request for discount @ http://decresearch.com/request-discount/232
Regionally speaking, it has been forecast that the United States will crop up as a prime growth avenue for the global healthcare IT industry, primarily driven by numerous investments in medical care infrastructure and government mandates. More than half a decade ago, The U.S. Department of Health and Human Services (HHS) had mandated the adoption of information technology by healthcare providers. A substantial growth has also been recorded in terms of investments by the U.S. government in healthcare IT since 2008.
A few years ago, the U.S. government had made an investment of about $20 billion through the HITECH (Health Information Technology for Economic and Clinical Health) Act, for setting up electronic health records. Aided by numerous government initiatives and the escalating need for an efficient healthcare management system, the U.S. healthcare IT industry is estimated to record substantial revenues by 2025.
Speaking of government initiatives, yet another regional ground touted to garner extensive proceeds in healthcare IT market is the United Kingdom. In December 2018, a new collaboration had been announced between the government and the life sciences industry, backed by a government fund worth 79 million, in order to study 5 million people and develop AI-centric diagnostic tests. Back in 2014, the UK government has also announced an investment of $5.4 billion in healthcare IT for a five-year period. It comes as no surprise therefore, that the UK healthcare IT market, powered by government initiatives, will reach $24.7 billion by the year 2025.
Get In-depth table of contents @ http://decresearch.com/toc/detail/healthcare-it-market
With the increasing prevalence of diseases and the subsequently rising demand for a sophisticated medical infrastructure, healthcare IT market contenders have been working to bring forth a slew of advancements in their service portfolio. For instance, McKesson Corporation has recently collaborated with technology leader Navigating Cancer to provide an enhanced Patient Relationship Management (PRM) platform for oncologists.
IT aided healthcare has come a long way since its inception. With massive changes in the technological landscape, many more innovations have been touted to disrupt the healthcare space. Powered by huge investments and the incorporation of advanced technologies in medical care management, healthcare IT market is expected to chart out a lucrative growth map in the forthcoming years.
Table Of Content
Chapter 1. Methodology
1.2. Market definition
1.3. Forecast parameters
1.4. Data sources
184.108.40.206. Paid sources
220.127.116.11. Unpaid sources
Chapter 2. Executive Summary
2.1. Healthcare information technology industry 3600 synopsis, 2014 - 2025
2.1.1. Business trends
2.1.2. Solution trends
2.1.3. End-use trends
2.1.4. Regional trends
Chapter 3. Healthcare Information Technology Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2014 - 2025
3.3. Industry impact forces
3.3.1. Growth drivers
18.104.22.168. Growing investment towards healthcare infrastructure development in Asia Pacific region
22.214.171.124. Growing adoption of artificial intelligence
126.96.36.199. High adoption of electronic health records in developed countries such as the U.S.
188.8.131.52. Favorable government initiatives
184.108.40.206. Increasing demand for cost-saving in healthcare delivery
3.3.2. Industry pitfalls & challenges
220.127.116.11. High cost associated with implementation and maintenance
18.104.22.168. Security and privacy concerns
3.4. Growth potential analysis
3.4.1. By solution
3.4.2. By end-use
3.5. Regulatory landscape
3.6. Technology landscape
3.7. Porter's analysis
3.8. Competitive landscape, 2017
3.8.1. Strategy dashboard
3.9. PESTEL analysis
Originally posted here:
Healthcare IT Market trends research and projections - GroundAlerts.com
Clene Nanomedicine Announces First Patient Dosed in the REPAIR-MS Clinical Trial for the Treatment of Multiple Sclerosis with Lead Nanocatalytic…
SALT LAKE CITY, Jan. 9, 2020 /PRNewswire/ --Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announcedthe dosing of the first patient enrolled in the Phase 2 REPAIR-MS study with its lead nanocatalytic therapy, CNM-Au8, for the treatment of Multiple Sclerosis (MS).
"The objective of the open-label, investigator-blinded REPAIR-MS study is to demonstrate improvements in brain bioenergetic metabolism in multiple sclerosis patients treated with CNM-Au8. Participants will undergo 31phosphorous magnetic resonance spectroscopy (31P-MRS) imaging to show how treatment with CNM-Au8 results in bioenergetic improvement of impaired neuronal redox state," said Robert Glanzman, MD, FAAN, Clene's Chief Medical Officer.
"We are excited to advance CNM-Au8 clinically into our second Phase 2 study for MS patients," said Rob Etherington, President and CEO of Clene. "Our preclinical data with CNM-Au8 demonstrated improvements in cellular bioenergetics, specifically within neurons and oligodendrocytes, which led to the initiation of the VISIONARY-MS Phase 2 study and now the REPAIR-MS Phase 2 trial. Currently, there are no therapies approved for remyelination and we believe CNM-Au8 has the strong potential for myelin repair and protection of neurons in patients with MS, which affects more than 2.5 million individuals worldwide and is one of the most common neurological disorders."
REPAIR-MS is Phase 2 single-center open label, sequential group, investigator blinded study examining the brain metabolic effects, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in patients who have been diagnosed with MS within 15 years of screening. Participants drink about 2 oz. dose (60 mL) of the nanocrystal suspension daily each morning for 12 weeks. The objective of this study is to advance pharmacologic understanding of CNM-Au8 treatment effects on central nervous system biomarkers related to bioenergetics, neuronal metabolism, and oxidative stress, as indicators of target engagement for CNM-Au8 in patients with MS. The study is taking place at University of Texas Southwestern Medical Center and is being led by Benjamin Greenberg, MD, an internationally recognized expert in treating rare autoimmune disorders of the central nervous system.
CNM-Au8 is a concentrated, aqueous suspension of clean-surfaced faceted nanocrystalline gold (Au) that acts catalytically to support important intracellular biological reactions. CNM-Au8 consists solely of gold atoms organized into faceted, geometrical crystals held in suspension in sodium bicarbonate buffered, pharmaceutical grade water. CNM-Au8 has demonstrated safety in Phase 1 studies in healthy volunteersand both remyelination and neuroprotection effects in multiple preclinical models. Preclinical data presented at scientific congresses demonstrated treatment with CNM-Au8 in neuronal cultures improved survival of dopaminergic neurons, protected neurite networks, decreased intracellular levels of reactive oxygen species, and improved mitochondrial capacity in response to cellular stress, induced by multiple disease-relevant neurotoxins. Oral treatment with CNM-Au8 restored functional behaviors in a rodent model of Parkinson's disease. CNM-Au8 has received regulatory approval to proceed to clinical studies for the treatment of remyelination failure in patients with multiple sclerosis and neuroprotection in patients with amyotrophic lateral sclerosis(ALS) and Parkinson's disease.
About Multiple Sclerosis
Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. Symptoms vary from person to person and range from numbness and tingling, to walking difficulties, fatigue, dizziness, pain, depression, blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with three times more women than men being diagnosed with the disease. A recent study led by the National MS Society estimates that nearly 1 million people are living with MS in the United States; twice as many than previously thought.
Clene Nanomedicine, Inc. is a privately-held, clinical-stage biopharmaceutical company, focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally-administered neurotherapeutic drugs. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland. For more information, please visit http://www.clene.com.
Investor ContactKaitlyn BroscoThe Ruth Group646firstname.lastname@example.org
Media Contact Kirsten ThomasThe Ruth Group508email@example.com
SOURCE Clene Nanomedicine, Inc.